“Partnering with Genesis Therapeutics presents a unique opportunity to leverage their AI technologies to accelerate the ...

Incyte and Genesis have entered a strategic partnership for the research, discovery and development of new small-molecule ...

Incyte (INCY) and Genesis Therapeutics announced that the companies have entered into a strategic collaboration focused on the research, ...

US biopharma Incyte and privately-held AI-focused biotech Genesis Therapeutics have entered into a strategic collaboration ...

Incyte and Genesis will leverage Genesis’ GEMS artificial intelligence (AI) platform to unlock the discovery of breakthrough ...

Incyte and Genesis Therapeutics have agreed to discover and optimize at least two initial small molecule compounds through Genesis’s AI platform, Genesis Exploration of Molecular Space (GEMS).

Artificial intelligence (AI) technology developer Genesis Therapeutics Inc. has brought in another larger partner to go on a search for the right therapeutic small molecules. The company is getting an ...

WILMINGTON, Del. & BURLINGAME, Calif. - Incyte (NASDAQ:INCY), a global biopharmaceutical company, has entered a strategic collaboration with Genesis Therapeutics, Inc ...

TD Cowen analyst Marc Frahm raised the firm’s price target on Incyte (INCY) to $88 from $86 and keeps a Buy rating on the shares. The firm said they reported a strong Q4 with Opzelura and Jakafi ...